Gatifloxacin: Difference between revisions

Jump to navigation Jump to search
No edit summary
(No difference)

Revision as of 14:57, 19 June 2009

Gatifloxacin
Clinical data
ATC code
Pharmacokinetic data
Protein binding20%
Elimination half-life7 to 14 hours
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H22FN3O4
Molar mass375.394 g/mol

WikiDoc Resources for Gatifloxacin

Articles

Most recent articles on Gatifloxacin

Most cited articles on Gatifloxacin

Review articles on Gatifloxacin

Articles on Gatifloxacin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Gatifloxacin

Images of Gatifloxacin

Photos of Gatifloxacin

Podcasts & MP3s on Gatifloxacin

Videos on Gatifloxacin

Evidence Based Medicine

Cochrane Collaboration on Gatifloxacin

Bandolier on Gatifloxacin

TRIP on Gatifloxacin

Clinical Trials

Ongoing Trials on Gatifloxacin at Clinical Trials.gov

Trial results on Gatifloxacin

Clinical Trials on Gatifloxacin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Gatifloxacin

NICE Guidance on Gatifloxacin

NHS PRODIGY Guidance

FDA on Gatifloxacin

CDC on Gatifloxacin

Books

Books on Gatifloxacin

News

Gatifloxacin in the news

Be alerted to news on Gatifloxacin

News trends on Gatifloxacin

Commentary

Blogs on Gatifloxacin

Definitions

Definitions of Gatifloxacin

Patient Resources / Community

Patient resources on Gatifloxacin

Discussion groups on Gatifloxacin

Patient Handouts on Gatifloxacin

Directions to Hospitals Treating Gatifloxacin

Risk calculators and risk factors for Gatifloxacin

Healthcare Provider Resources

Symptoms of Gatifloxacin

Causes & Risk Factors for Gatifloxacin

Diagnostic studies for Gatifloxacin

Treatment of Gatifloxacin

Continuing Medical Education (CME)

CME Programs on Gatifloxacin

International

Gatifloxacin en Espanol

Gatifloxacin en Francais

Business

Gatifloxacin in the Marketplace

Patents on Gatifloxacin

Experimental / Informatics

List of terms related to Gatifloxacin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin® for the treatment of respiratory tract infections, having licensed the medication from Kyorin Pharmaceutical Company of Japan. Allergan produces an eye-drop formulation called Zymar®. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy.

Side-effects and removal from the market

A Canadian study published in the New England Journal of Medicine in March 2006 claims Tequin® can have "life threatening" side effects including serious diabetes.[1] An editorial by Dr. Jerry Gurwitz in the same issue called for the Food and Drug Administration (FDA) to consider giving Tequin® a black box warning.[2] This editorial followed distribution of a letter dated February 15 by Bristol-Myers Squibb to health care providers indicating action taken with the FDA to strengthen warnings for the medication.[3] Subsequently it was reported on May 1, 2006 that Bristol-Myers Squibb would stop manufacture of Tequin, end sales of the drug after existing stockpiles were exhausted, and return all rights to Kyorin.[4]

Gatifloxacin is now only available in the US as an opthalmic solution.

Notes

  1. Park-Wyllie, Laura Y. (2006). "Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults". The New England Journal of Medicine. 354 (13): 1352&ndash, 1361. PMID 16510739. Retrieved 2006-05-01. Unknown parameter |month= ignored (help); Unknown parameter |coauthors= ignored (help) Note: publication date 30 March; available on-line 1 March
  2. Gurwitz, Jerry H. (2006). "Serious Adverse Drug Effects — Seeing the Trees through the Forest". The New England Journal of Medicine. 354 (13): 1413&ndash, 1415. PMID 16510740. Retrieved 2006-05-01. Unknown parameter |month= ignored (help)
  3. Lewis-Hall, Freda (February 15, 2006). "Dear Healthcare Provider:" (PDF). Bristol-Myers Squibb. Retrieved May 1. Unknown parameter |accessyear= ignored (|access-date= suggested) (help); Check date values in: |accessdate= (help)
  4. Schmid, Randolph E. (May 1, 2006). "Drug Company Taking Tequin Off Market". Associated Press. Retrieved May 1, 2006.


Template:QuinoloneAntiBiotics Template:SIB th:กาติฟลอกซาซิน

Template:WikiDoc Sources